London, Feb 27, 2026, 09:25 GMT — Regular session
- Haleon moved up roughly 1% early Friday, rebounding after a pair of choppy sessions sparked by its results.
- Sentiment is still anchored to the company’s 2026 growth outlook and its buyback plan.
- Coming up, Haleon is set to release its Q1 trading statement and hold its AGM on April 29.
Haleon HLN.L picked up 1.0% to 398.2 pence during early London hours Friday. Shares moved in a range from 393.8 to 399.9 pence for the session.
Haleon shares have been volatile this week, after the company posted 2025 revenue of 11.03 billion pounds and gave a wary 2026 outlook that shifted focus back to U.S. demand. The Sensodyne maker is targeting 3%-5% organic revenue growth in 2026—organic here excludes currency shifts and M&A—and earmarked 500 million pounds for buybacks. “2025 organic growth of 3% fell short of medium-term expectations,” CEO Brian McNamara said, citing sluggish cold-and-flu sales and weak North American consumer confidence. Haleon Corporate
It’s a key question for investors: can Haleon deliver U.S. volume gains without sacrificing margin? Across consumer health, price hikes have done much of the heavy lifting—but that strategy runs into trouble when customers start trading down.
The shares slid 6.85% Wednesday to 3.78 pounds, then clawed back 4.31% Thursday, closing at 3.94 pounds. Both sessions saw volume running higher than what’s typical lately. Not the usual price action for a defensive stock, and the trading remains choppy.
CFO Dawn Allen, speaking during the results presentation, highlighted that Haleon posted “strong organic operating profit of 10.5% and free cash flow of £1.9 billion” for 2025. Still, she acknowledged, “we are not satisfied with our organic revenue growth.” Management pointed to a North American rebound in 2026 as the company continues to reshape its operations in that region. MarketScreener
McNamara told Reuters he’s looking for U.S. growth this year, with Haleon aiming to get back into that 4%-6% medium-term range by 2027. The company’s focus, he said, will swing towards grabbing share and pushing volumes, not hiking U.S. prices any further. He flagged competitors ramping up promotions, plus a double-digit drop in its Smokers’ Health line, as factors weighing on recent performance. “Many households feel financially stretched,” Quilter Cheviot analyst Chris Beckett added. Reuters
Haleon’s board is putting forward a 2025 total dividend of 7.1 pence per share, with a 4.9 pence final dividend in the mix. If shareholders sign off, that final payout lands on May 14. The record date comes up April 10. Shares lose the right to the dividend on April 9 for ordinary shares, while U.S. ADS holders have April 10 as their cutoff. The window to elect dividend reinvestment shuts April 24.
The forecast relies on a rebound in U.S. demand and a return to typical seasonal patterns. Shoppers sticking with cheaper options—or if discounting persists in vitamins and other OTC products—the anticipated “back-half” recovery risks losing its luster again.
Haleon is set to deliver its Q1 trading update on April 29, lining up with the annual general meeting. Investors want to hear signs that North America isn’t slipping further, and will be watching for details on how quickly buybacks might ramp up.
